Effect of haridradi yog in covid-19 recovered patients of diabetes mellitus type 2
Phase 3
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2022/08/044566
- Lead Sponsor
- Madan Mohan Malviya Government Ayurved College udaipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Diabetic Patients who recovered from the Covid-19 infection.
2.The patiens having clinical sign & symptoms of Madhumeha/Diabetes Mallitus
Exclusion Criteria
1. Patients having IDDM (type -1 )
2. Cronic Complications (microvascular & macrovascular0
3. patients who have not been infected with Covid 19 infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Improvement in sign & symptoms of madhumeha <br/ ><br>2.improvement in Blood sugarTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method 1. Improvement in sign & symptoms of madhumeha <br/ ><br>2.improvement in Blood sugarTimepoint: 8 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Haridradi Yog target in post-COVID-19 Type 2 diabetes mellitus (T2DM) patients?
How does Haridradi Yog compare to metformin or SGLT2 inhibitors in improving glycemic control after SARS-CoV-2 recovery in T2DM?
Which biomarkers correlate with Haridradi Yog's therapeutic efficacy in post-COVID T2DM patients with metabolic dysregulation?
What adverse events are associated with Haridradi Yog in T2DM patients with prior SARS-CoV-2 infection, and how are they managed?
Are there Ayurvedic compounds or combination therapies synergistic with Haridradi Yog for post-COVID T2DM complications?